Tenaya Therapeutics is a technology company.
Tenaya Therapeutics has raised $202.0M across 2 funding rounds.
Tenaya Therapeutics has raised $202.0M in total across 2 funding rounds.
Tenaya Therapeutics is not a technology company—it is a clinical-stage biotechnology company focused on discovering, developing, and delivering curative therapies for heart disease.[1][3]
Tenaya Therapeutics is a precision medicine company dedicated to addressing the underlying genetic causes of cardiovascular disease rather than merely treating symptoms.[2] The company develops therapies across three platforms: gene therapy, cellular regeneration, and precision medicine approaches.[5] Its lead programs include TN-201 for *MYBPC3*-associated hypertrophic cardiomyopathy (HCM) and TN-401 for *PKP2*-associated arrhythmogenic right ventricular cardiomyopathy (ARVC), alongside TN-301, a small molecule HDAC6 inhibitor for heart failure with preserved ejection fraction (HFpEF).[3][6]
The company's mission centers on discovering and delivering therapies that target the root causes of heart disease, particularly rare genetic cardiomyopathies and more prevalent heart conditions.[1][3] Tenaya operates with a patient-first philosophy, actively incorporating feedback from patients and families throughout its drug development process to ensure treatments address real clinical needs.[3]
Tenaya was founded by leading cardiovascular scientists from the Gladstone Institutes and UT Southwestern Medical Center.[2][3] The company emerged from a breakthrough in three-dimensional human heart tissue engineering developed through collaboration between UC Berkeley Professor Kevin Healy and researchers at Gladstone Institutes.[5] This foundational technology—which required a thousand-fold fewer cells than competing tissue engineering techniques—enabled a more efficient, cost-effective approach to disease modeling and drug testing.[5] Dr. Benoit G. Bruneau, a Scientific Founder, contributed critical expertise in cardiovascular biology and disease pathway identification.[4]
Tenaya's competitive advantages include:
Tenaya operates within a rapidly evolving biotechnology sector focused on gene therapy and precision medicine for rare genetic diseases.[4] The company addresses a significant market opportunity: rare cardiomyopathies represent severe, life-threatening conditions with limited treatment options, and the precision medicine approach allows Tenaya to target specific genetic drivers of disease rather than developing broad-spectrum treatments.[4] The timing is favorable, as advances in gene therapy delivery systems, stem cell technology, and genetic sequencing have made targeted cardiovascular treatments increasingly feasible.[5] By establishing a niche in genetic heart disease treatment, Tenaya influences the broader ecosystem by demonstrating how precision medicine and advanced tissue engineering can transform treatment paradigms for conditions previously considered untreatable.[4]
Tenaya's trajectory depends on advancing its clinical-stage programs through regulatory approval while expanding its pipeline into additional genetic and acquired heart conditions.[1] The company's long-term vision is to become a fully integrated biopharmaceutical company offering multiple modalities—gene replacement, gene editing, small molecules, gene silencing, and regenerative medicine—for cardiovascular disease.[2] Success will require demonstrating clinical efficacy in its lead programs, securing manufacturing scale-up, and potentially establishing additional partnerships to accelerate development. As gene therapy gains regulatory acceptance and reimbursement pathways clarify, companies like Tenaya that combine deep scientific expertise with patient-centric development approaches are well-positioned to deliver transformative treatments for millions of patients with genetic heart disease.
Tenaya Therapeutics has raised $202.0M in total across 2 funding rounds.
Tenaya Therapeutics's investors include Apollo Health Ventures, GV, RTW Investments.
Tenaya Therapeutics has raised $202.0M across 2 funding rounds. Most recently, it raised $110.0M Series C in February 2021.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Feb 1, 2021 | $110.0M Series C | Apollo Health Ventures, GV, RTW Investments | |
| Oct 1, 2019 | $92.0M Series B | Apollo Health Ventures, GV |